Cargando…

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer

PURPOSE: We sought to expand the currently limited, Canadian, population-based data on the characteristics, treatment pathways, and health care costs according to stage in patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC). METHODS: We extracted data from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brezden-Masley, Christine, Fathers, Kelly E., Coombes, Megan E., Pourmirza, Behin, Xue, Cloris, Jerzak, Katarzyna J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921035/ https://www.ncbi.nlm.nih.gov/pubmed/33090268 http://dx.doi.org/10.1007/s10549-020-05976-w

Ejemplares similares

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Redefining Heart Failure in Breast Cancer
por: Volgman, Annabelle Santos, et al.
Publicado: (2022)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada
por: Rampakakis, Emmanouil, et al.
Publicado: (2019)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Cancer and Cardiovascular Disease: The Complex Labyrinth
por: Dent, Susan, et al.
Publicado: (2015)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population
por: Abadir, Amir, et al.
Publicado: (2012)

Assessing the validity of administrative health data for the identification of children and youth with autism spectrum disorder in Ontario
por: Brooks, Jennifer D., et al.
Publicado: (2021)

Treatment of HR+/HER2− breast cancer in urban mainland China: results from the CancerMPact Survey 2019
por: Murali, Bhavna, et al.
Publicado: (2022)

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2023)

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Utilization and cost of electronic resources in adult cancer center
por: Maraiki, Fatma, et al.
Publicado: (2018)

A Population-Based Study of Care at the End of Life Among People With HIV in Ontario From 2010 to 2013
por: Kendall, Claire E., et al.
Publicado: (2017)

Colonoscopy resource availability and colonoscopy utilization in Ontario, Canada
por: Webber, Colleen, et al.
Publicado: (2017)

Firearm injury epidemiology in children and youth in Ontario, Canada: a population-based study
por: Saunders, Natasha Ruth, et al.
Publicado: (2021)

Screening behaviours, demographics, and stage at diagnosis in the publicly funded Ontario Breast Screening Program
por: Gold, Nicholas, et al.
Publicado: (2023)

Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
por: Burger, E A, et al.
Publicado: (2012)

HER2-LOW BREAST CANCER BRAIN METASTASES: INCIDENCE AND TREATMENT IMPLICATIONS
por: Chehade, Rania, et al.
Publicado: (2023)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Modest rise in chlamydia and gonorrhoea testing did not increase case detection in a clinical HIV cohort in Ontario, Canada
por: Burchell, Ann N, et al.
Publicado: (2014)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bebs1h43de6pc52d0pahq7ir6u